Table 2 Comparisons between patients with UC diagnosed in the prebiologic and biologic era.

From: Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000

 

Prebiologic era

Biologic era

P value

Number of patients

44 (23.7%)

142 (76.3%)

 

Gender, male (n [%])

33 (75.0%)

102 (71.8%)

0.681

Age at the time of diagnosis, years, Mean (SD)

24.3 (10.6)

31.9 (16.0)

 < 0.001

Disease duration, years, Mean (SD)

24.8 (6.0)

7.4 (4.9)

 < 0.001

CDAI at diagnosis, Mean (SD)

72.5 (62.7)

44.2 (45.5)

0.003

Treatment

   

Biological treatment

36 (81.8%)

110 (77.5%)

0.539

IFX (n [%])

30 (68.2%)

74 (52.1%)

0.061

IFX-BS (n [%])

4 (9.1%)

32 (22.5%)

0.049

ADA (n [%])

12 (27.3%)

45 (31.7%)

0.579

UST (n [%])

2 (4.5%)

14 (9.9%)

0.272

Other treatment

   

5-ASA (n [%])

40 (90.9%)

111 (78.2%)

0.059

Corticosteroids

23 (52.2%)

59 (41.5%)

0.191

Immunomodulator (n [%])

17 (38.6%)

70 (49.3%)

0.245

Apheresis (n [%])

2 (4.5%)

12 (8.5%)

0.385

Probiotics (n [%])

28 (64.6%)

88 (62.0%)

0.801

Elemental diet (n [%])

24 (54.5%)

63 (44.4%)

0.111

Dose of elemental diet, kcal (SD)

806.3 (389.9)

660.3 (285.4)

 

Herbal drug (n [%])

2 (4.5%)

10 (7.0%)

0.579